Reply

Abstract
To the Editor —We appreciate the letter from Parienti et al. [1] regarding our study [2] on once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus (HIV)–infected patients. Parienti et al. bring to our attention their concern that once-daily regimens may increase drug holidays, thereby favoring the emergence of viral resistance and, eventually, of treatment failure

This publication has 0 references indexed in Scilit: